Translational Workshop 1: Spatial Omics for Prediction, Prognostication, and Mechanistic Insights
Session Details
This session will highlight advances in spatial omics—including proteomics, metabolomics, and glycomics—for improving prediction, prognostication, and mechanistic understanding in breast cancer, followed by an advocate perspective and panel discussion.
Presentation numberWS1-01
Proteomics
Sandro Santagata, Brigham and Women's Hospital, Boston, MA
Presentation numberWS1-02
Metabolomics
Ralph J DeBerardinis, UT Southwestern Medical Center, Dallas, TX
Presentation numberWS1-03
Transcriptomics
Daniel L. Abravanel, Dana-Farber Cancer Institute, Boston, MA
D. L. Abravanel; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Although metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. We assembled a multi-modal spatial and cellular map of 67 tumor biopsies from 60 patients with metastatic breast cancer across diverse clinicopathological features and nine anatomic sites with detailed clinical annotations. We combined single-cell or single-nucleus RNA sequencing for all biopsies with a panel of four spatial expression assays (Slide-seq, MERFISH, ExSeq and CODEX) and H&E staining of consecutive serial sections from up to 15 of these biopsies. We leveraged the coupled measurements to provide reference points for the utility and integration of different experimental techniques and used them to assess variability in cell type composition and expression as well as emerging spatial expression characteristics across clinicopathological and methodological diversity. Finally, we assessed spatial expression and co-localization features of macrophage populations, characterized three distinct spatial phenotypes of epithelial-to-mesenchymal transition and identified expression programs associated with local T cell infiltration versus exclusion, showcasing the potential of clinically relevant discovery in such maps.
Moderator
Leif W. Ellisen, Mass General Hospital/Harvard Medical School, Boston, MA
Advocate
Jane Perlmutter, Gemini Group, Ann Arbor, MI